{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-021753","form_type":"8-K","ticker":"PRCT","cik":"0001588978","company_name":"PROCEPT BioRobotics Corp","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.171708+00:00","generated_at":"2026-06-28T12:59:56.264342+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PROCEPT Q3 revenue $8.7M up 314% YoY; raises FY 2021 guide to $33.0-$33.3M","bullets":["Total revenue of $8.7M vs. $2.1M in Q3 2020; U.S. system revenue $5.0M vs. $0.6M.","Net loss of $14.1M; cash and short-term investments $320.5M after $172.4M IPO net proceeds.","Gross margin 48.9%, up from -1% in Q3 2020 and 42.2% in Q2 2021.","Full-year 2021 revenue guidance raised to $33.0-$33.3M.","Cigna adopted positive coverage policy for Aquablation, adding 16M covered lives effective Sept 15, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-021753","json":"https://secwatch.observer/filing/0001628280-21-021753.json","markdown":"https://secwatch.observer/filing/0001628280-21-021753.md","text":"https://secwatch.observer/filing/0001628280-21-021753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1588978/000162828021021753/0001628280-21-021753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1588978/000162828021021753/prct-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:59:56.264342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}